Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 2

Status

Unknown 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 4

Conditions

Breast Neoplasms 31Advanced Solid Tumors 25Advanced Solid Tumor 24Carcinoma, Non-Small-Cell Lung 20Neoplasms 15Solid Tumor 12Prostatic Neoplasms 12Multiple Myeloma 12Neoplasm Metastasis 11Recurrence 10Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Ovarian Neoplasms 9Lung Neoplasms 9Stomach Neoplasms 8Melanoma 8Lymphoma, Large B-Cell, Diffuse 8Leukemia, Myeloid, Acute 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Sarcoma 7Colorectal Neoplasms 7Uterine Cervical Neoplasms 6Solid Tumors 6Carcinoma, Transitional Cell 5Advanced Solid Tumour 5Squamous Cell Carcinoma of Head and Neck 4Nasopharyngeal Carcinoma 4Myelodysplastic Syndromes 4Lymphoma 4

Interventions

Gemcitabine 12Cisplatin 11pembrolizumab 6Docetaxel 5Capecitabine 5camrelizumab 4Injections 4toripalimab 3spartalizumab 3penpulimab 2famitinib 2SHR-1701 2Carboplatin 218-O-demethylcervinomycin A2 2tislelizumab 1icotinib 1donafenib 1cc-486 1Valganciclovir 1Radiotherapy, Intensity-Modulated 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Medicare Part B 1Ipilimumab 1Immunotherapy 1Fluorouracil 1Drug Therapy 1Biological Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Nasopharyngeal Carcinoma × Injections × Clear all
NCT05294172 2026-05-08

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 3 Active not recruiting
295 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT03121716 2022-07-12

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
23 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT03707509 2022-07-01

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
263 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT04282070 2021-12-21

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown
91 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡